

#9

SEQUENCE LISTING



<110> Ziwei Huang
 Jiansong Luo
 Zhaowen Luo
 Naming Zhou

<120> A Novel Peptide Antagonist of CXCR4
 Derived from the N-Terminus of Viral Chemokine vMIP-II

<130> HUA01-NP007

<140> 09/773,830

<141> 2001-02-01

<150> 60/180,487

<151> 2000-02-03

<160> 33

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 71

<212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 1

Leu	Gly	Ala	Ser	Trp	His	Arg	Pro	Asp	Lys	Cys	Cys	Leu	Gly	Tyr	Gln
1				5					10					15	
Lys	Arg	Pro	Leu	Pro	Gln	Val	Leu	Leu	Ser	Ser	Trp	Tyr	Pro	Thr	Ser
		20						25					30		
Gln	Leu	Cys	Ser	Lys	Pro	Gly	Val	Ile	Phe	Leu	Thr	Lys	Arg	Gly	Arg
		35					40					45			
Gln	Val	Cys	Ala	Asp	Lys	Ser	Lys	Asp	Trp	Val	Lys	Lys	Leu	Met	Gln
	50					55					60				
Gln	Leu	Pro	Val	Thr	Ala	Arg									
65						70									

<210> 2

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 2

Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln

1 5 10 15
Lys Arg Pro Leu Pro
20

Lys Pro Val Ser His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln Lys
 1 5 10 15
 Arg Pro Leu Pro
 20

<210> 7
 <211> 23
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> v-MIPII derived peptide

<400> 7
 Gln Val Leu Leu Ser Ser Trp Tyr Pro Thr Ser Gln Leu Cys Ser Lys
 1 5 10 15
 Pro Gly Val Ile Phe Leu Thr
 20

<210> 8
 <211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> v-MIPII derived peptide

<400> 8
 Ser Lys Pro Gly Val Ile Phe Leu Thr Lys Arg Gly Arg Gln Val Cys
 1 5 10 15
 Ala Asp Lys Ser Lys Asp
 20

<210> 9
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> v-MIPII derived peptide

<400> 9
 Ala Asp Lys Ser Lys Asp Trp Val Lys Lys Leu Met Gln Gln Leu Pro
 1 5 10 15
 Val Thr Ala Arg
 20

<210> 10
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> v-MIPPII derived peptide
 <400> 10
 Cys Thr Ser Gln Leu Ala Ser Lys Pro Gly Cys
 1 5 10

<210> 11
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> v-MIPPII derived peptide

<400> 11
 Cys Phe Leu Thr Lys Arg Gly Arg Gln Val Cys
 1 5 10

<210> 12
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> v-MIPPII derived peptide

<400> 12
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Ala Ala Leu Gly Tyr Gln
 1 5 10 15
 Lys Arg Pro Leu Pro
 20

<210> 13
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> v-MIPPII derived peptide

<400> 13
 Ala Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
 1 5 10 15
 Lys Arg Pro Leu Pro
 20

<210> 14
 <211> 21
 <212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 14

Leu	Gly	Ala	Ser	Ala	His	Arg	Pro	Asp	Lys	Cys	Cys	Leu	Gly	Tyr	Gln
1				5					10					15	
Lys	Arg	Pro	Leu	Pro											
			20												

<210> 15

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 15

Leu	Gly	Ala	Ser	Trp	His	Ala	Pro	Asp	Lys	Cys	Cys	Leu	Gly	Tyr	Gln
1				5					10					15	
Lys	Arg	Pro	Leu	Pro											
			20												

<210> 16

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 16

Leu	Gly	Ala	Ser	Trp	His	Arg	Pro	Asp	Ala	Cys	Cys	Leu	Gly	Tyr	Gln
1				5					10					15	
Lys	Arg	Pro	Leu	Pro											
			20												

<210> 17

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 17

Leu	Gly	Ala	Ser	Trp	His	Arg	Pro	Asp	Lys	Ala	Cys	Leu	Gly	Tyr	Gln
1				5					10					15	
Lys	Arg	Pro	Leu	Pro											
			20												

<210> 18
 <211> 21
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> v-MIPIII derived peptide

 <400> 18
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Ala
 1 5 10 15
 Lys Arg Pro Leu Pro
 20

<210> 19
 <211> 21
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> v-MIPIII derived peptide

 <400> 19
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
 1 5 10 15
 Lys Ala Pro Leu Pro
 20

<210> 20
 <211> 21
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> v-MIPIII derived peptide

 <400> 20
 Pro Leu Pro Arg Lys Gln Tyr Gly Leu Cys Cys Lys Asp Pro Arg His
 1 5 10 15
 Trp Ser Ala Gly Leu
 20

<210> 21
 <211> 21
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> v-MIPIII derived peptide

<400> 21
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
 1 5 10 15
 Lys Arg Pro Leu Pro
 20

<210> 22
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> v-MIPII derived peptide

<400> 22
 Pro Leu Pro Arg Lys Gln Tyr Gly Leu Cys Cys Lys Asp Pro Arg His
 1 5 10 15
 Trp Ser Ala Gly Leu
 20

<210> 23
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> v-MIPII derived peptide

<400> 23
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
 1 5 10 15
 Lys Arg Pro Leu Pro
 20

<210> 24
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> v-MIPII derived peptide

<400> 24
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
 1 5 10 15
 Lys Arg Pro Leu Pro
 20

<210> 25
 <211> 21
 <212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 25

Ala	Gly	Ala	Ser	Trp	His	Arg	Pro	Asp	Lys	Cys	Cys	Leu	Gly	Tyr	Gln
1				5					10					15	
Lys	Arg	Pro	Leu	Pro											
			20												

<210> 26

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 26

Leu	Gly	Ala	Ser	Ala	His	Arg	Pro	Asp	Lys	Cys	Cys	Leu	Gly	Tyr	Gln
1				5					10					15	
Lys	Arg	Pro	Leu	Pro											
			20												

<210> 27

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 27

Leu	Gly	Ala	Ser	Trp	His	Ala	Pro	Asp	Lys	Cys	Cys	Leu	Gly	Tyr	Gln
1				5					10					15	
Lys	Arg	Pro	Leu	Pro											
			20												

<210> 28

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 28

Leu	Gly	Ala	Ser	Trp	His	Arg	Pro	Asp	Ala	Cys	Cys	Leu	Gly	Tyr	Gln
1				5					10					15	
Lys	Arg	Pro	Leu	Pro											
			20												

<210> 29
 <211> 21
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> v-MIPII derived peptide

 <400> 29
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Ala Cys Leu Gly Tyr Gln
 1 5 10 15
 Lys Arg Pro Leu Pro
 20

<210> 30
 <211> 21
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> v-MIPII derived peptide

 <400> 30
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Ala
 1 5 10 15
 Lys Arg Pro Leu Pro
 20

<210> 31
 <211> 21
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> v-MIPII derived peptide

 <400> 31
 Leu Gly Ala Ser Trp His Arg Pro Asp Lys Cys Cys Leu Gly Tyr Gln
 1 5 10 15
 Lys Ala Pro Leu Pro
 20

<210> 32
 <211> 21
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> v-MIPII derived peptide

<400> 32

Leu Gly Ala Ser Trp His Arg Pro Asp Lys Ala Ala Leu Gly Tyr Gln
1 5 10 15
Lys Arg Pro Leu Pro
20

<210> 33

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> v-MIPII derived peptide

<400> 33

Leu Gly Ala Ser Trp His Arg Pro Asp Lys
1 5 10

TRANSMIT CONFIRMATION REPORT

NO.	:	002	
RECEIVER	:		USPTO
TRANSMITTER	:	TJU/UNIV. COUNSEL	
DATE	:	JUN 14'02	10:51
DURATION	:	09'10	
MODE	:	STD	
PAGES	:	14	
RESULT	:	OK	